Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...
Cytokinetics started at buy by Stifel, aficamten highlighted
Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...
Royalty Pharma simplifies corporate structure with $1.1 billion deal
Founded by Mexican billionaire and former Lazard banker Pablo Legorreta, the firm buys royalties on potential blockbuster drugs from academic labs and biotechnology companies, which in turn use the ...
Investing16d
Cytokinetics’ SWOT analysis: aficamten progress boosts stock outlook
The company’s lead candidate, aficamten, has been advancing steadily through the regulatory process. Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food and ...
Investing16d
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook
The company's lead candidate, aficamten, has been advancing steadily through the regulatory process. Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food ...
Yahoo Finance18d
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...